Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study
| Autor: | Takenobu Iso, Yasuyuki Tamura, Hiroshi Inoue, Koichi Okamura, Kenji Takagishi, Tetsuya Kaneko, Masatoshi Matsushita, Keio Ayabe, Keiko Otsuka, Kimihiko Takeuchi, Chisa Okura, Yukio Yonemoto |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male musculoskeletal diseases medicine.medical_specialty Adolescent Combination therapy Blood Sedimentation Gastroenterology Arthritis Rheumatoid Cohort Studies Young Adult 03 medical and health sciences 0302 clinical medicine Double-Blind Method Rheumatology Internal medicine medicine Humans In patient 030212 general & internal medicine skin and connective tissue diseases Adverse effect Aged Aged 80 and over 030203 arthritis & rheumatology medicine.diagnostic_test business.industry Antibodies Monoclonal Middle Aged medicine.disease Golimumab Surgery C-Reactive Protein Methotrexate Treatment Outcome Antirheumatic Agents Rheumatoid arthritis Erythrocyte sedimentation rate Drug Therapy Combination Female Matrix Metalloproteinase 3 business human activities medicine.drug Cohort study |
| Zdroj: | Modern Rheumatology. 26:24-28 |
| ISSN: | 1439-7609 1439-7595 |
| Popis: | The aim of this study was to compare the efficacy and safety of golimumab (GLM) 50 mg + methotrexate (MTX) combination therapy and GLM 100 mg monotherapy in patients with rheumatoid arthritis (RA).The subjects were 115 RA patients (92 females and 23 males; median (range) age, 64 (17-87) years; median (range) disease duration, 8 (0.6-48) years) started on GLM. Eighty-three patients received GLM 50 mg/4 weeks + MTX (C group; median (range) MTX dosage 8 (2-16) mg/week), and 32 patients received GLM 100 mg/4 weeks (M group). Serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), matrix metalloproteinase-3, disease activity score (DAS) 28-ESR, DAS28-CRP, simplified disease activity index, and clinical disease activity index were evaluated 4, 12, and 24 weeks after starting GLM.There were no significant differences in disease activity, adverse events, and drug continuation rates at 24 weeks between the groups. The DAS28-ESR remission rate was 34% in the C group and 26% in the M group.GLM 100 mg monotherapy improved disease activity as well as GLM 50 mg + MTX combination therapy. GLM 100 mg monotherapy appears to have a sufficient therapeutic effect in RA patients who cannot take MTX. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|